SRNG

Soaring Eagle Acquisition Corp. [SRNG] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

SRNG Stock Summary

In the News

04:32 29 Mar 2024 SRNG

Ginkgo Investigation Alert: Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claims on Behalf of Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) Investors

RADNOR, Pa., Oct. 8, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP is currently investigating potential violations of the federal securities laws on behalf of shareholders of Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) ("Ginkgo") f/k/a Soaring Eagle Acquisition Corp. (Nasdaq: SRNG) ("Soaring Eagle").

01:12 29 Mar 2024 SRNG

DNA Stock Cooks Up 10% Gains on Ginkgo Biowork's First Trading Day

Ginkgo Bioworks knows about growth and so far, it seems as though DNA stock does as well as it kicks off under an aptly titled ticker. The post DNA Stock Cooks Up 10% Gains on Ginkgo Biowork's First Trading Day appeared first on InvestorPlace.

07:00 29 Mar 2024 SRNG

Ginkgo Bioworks to Begin Trading Today as NYSE: DNA with Over $1.6 Billion in Proceeds

BOSTON, Sept. 17, 2021 /PRNewswire/ -- Ginkgo Bioworks, Inc. ("Ginkgo") and Soaring Eagle Acquisition Corp. (Nasdaq: SRNG) ("Soaring Eagle"), a special purpose acquisition company, today announced the closing of their previously announced business combination.

01:39 29 Mar 2024 SRNG

Dear SRNG Stock Fans, Mark Your Calendars for Ginkgo Bioworks' Debut on Sept. 17

Soaring Eagle Acquisition is about to complete its merger with Ginkgo Bioworks, and SRNG stock is reacting well. Here's why.

11:16 29 Mar 2024 SRNG

All Aboard For The BioRevolution

BioRevolution is a new and rapidly growing set of tools that are increasingly allowing us to read, write and hack that code of life with greater speed and precision and a rapidly decreasing cost. Health care is the most mature sector of those we are investing in, and even in health care, it's still early.

07:12 29 Mar 2024 SRNG

Is Ginkgo Bioworks Worth the Hype?

The synthetic biology company is going public through one of the largest SPAC mergers in history. Is the stock worth paying up for?

06:17 29 Mar 2024 SRNG

3 Life Science Stocks Cathy Wood's Buying Hand Over Fist Right Now

ARK Invest made multiple purchases of these stocks last week.

12:45 29 Mar 2024 SRNG

Soaring Eagle Announces Extraordinary General Meeting Date for Proposed Business Combination with Ginkgo

NEW YORK--(BUSINESS WIRE)-- #ginkgobioworks--Soaring Eagle Acquisition Corp., a Cayman Islands exempted company limited by shares (the “Company” or “Soaring Eagle”) (Nasdaq: SRNG.U, SRNG, SRNG WS), announced today that it has scheduled the extraordinary general meeting of the Company's shareholders (the "Special Meeting") in connection with its business combination (the "Business Combination") with Ginkgo Bioworks, Inc. to be held on September 14, 2021. Notice of the Special Meeting and a proxy statement/prospec

11:40 29 Mar 2024 SRNG

Cathie Wood's Ark Invest just doubled a multi-million-share position in a SPAC merging with Ginkgo Bioworks

Ark Invest first began purchasing shares of the Ginkgo Bioworks SPAC on August 3 and now owns 14.5 million shares worth about $150 million.

07:32 29 Mar 2024 SRNG

Soaring Eagle: SPAC Merger With Promising Synthetic Biology Specialist, Ginkgo Bioworks

Ginkgo Bioworks, Inc. and Soaring Eagle Acquisition Corp., a special purpose acquisition company, have announced their $17B merger transaction will finalize in Q3'21 resulting in Ginkgo earning a $15B EV. Ginkgo Bioworks is a high-growth analytical biotechnology company applying automation for contract-based cell engineering utilizing a combination of computational and synthetic biological practices.

SRNG Financial details

Company Rating
Buy
Market Cap
0
Income
-
Revenue
-
Book val./share
8.53
Cash/share
0
Dividend
-
Dividend %
-
Employees
-
Optionable
No
Shortable
Yes
Earnings
-
P/E
0
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
-
P/FCF
-
Quick Ratio
-
Current Ratio
-
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
1.13%
SMA50
-4.79%
SMA100
-
Inst Own
0%
Inst Trans
0%
ROA
-
ROE
-
ROC
-
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
172.5M
Shs Float
172.5M
-
-
-
-
Target Price
-
52W Range
10.01-11.5
52W High
-84.18%
52W Low
-82.6%
RSI
46
Rel Volume
3.68
Avg Volume
5.01M
Volume
18.43M
Perf Week
-4.92%
Perf Month
10.83%
Perf Quarter
-
Perf Half Y
-20.55%
-
-
-
-
Beta
-
-
-
Volatility
0.03%, 0.15%
Prev Close
-1.14%
Price
1.74
Change
-1.14%

SRNG Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2020-12-31

Metric History 2020-12-31
2.02K
Revenue per share
0
Net income per share
0
Operating cash flow per share
0
Free cash flow per share
0
Cash per share
0
Book value per share
0
Tangible book value per share
0
Share holders equity per share
0
Interest debt per share
0
Market cap
0
Enterprise value
300K
P/E ratio
0
Price to sales ratio
0
POCF ratio
0
PFCF ratio
0
P/B Ratio
0
PTB ratio
0
EV to sales
0
Enterprise value over EBITDA
0
EV to operating cash flow
0
EV to free cash flow
0
Earnings yield
0
Free cash flow yield
0
Debt to equity
15
Debt to assets
0.24
Net debt to EBITDA
0
Current ratio
0
Interest coverage
0
Income quality
0
Dividend Yield
0
Payout ratio
0
Sales general and administrative to revenue
0
Research and developement to revenue
0
Intangibles to total assets
0
Capex to operating cash flow
0
Capex to revenue
0
Capex to depreciation
0
Stock based compensation to revenue
0
Graham number
0
ROIC
0
Return on tangible assets
0
Graham Net
0
Working capital
-1.23M
Tangible asset value
20K
Net current asset value
-1.23M
Invested capital
15
Average receivables
0
Average payables
0
Average inventory
0
Days sales outstanding
0
Days payables outstanding
0
Days of inventory on hand
0
Receivables turnover
0
Payables turnover
0
Inventory turnover
0
ROE
0
Capex per share
0

Quarterly Fundamentals Overview

Last date of statement is 2021-06-30 for Q2

Metric History 2021-06-30
2.02K
Revenue per share
0
Net income per share
-0.62
Operating cash flow per share
-0.01
Free cash flow per share
-0.01
Cash per share
0
Book value per share
8.53
Tangible book value per share
8.53
Share holders equity per share
8.53
Interest debt per share
0
Market cap
1.72B
Enterprise value
1.72B
P/E ratio
-4.02
Price to sales ratio
0
POCF ratio
-745.66
PFCF ratio
-745.66
P/B Ratio
1.17
PTB ratio
1.17
EV to sales
0
Enterprise value over EBITDA
-16.09
EV to operating cash flow
-745.64
EV to free cash flow
-745.64
Earnings yield
-0.06
Free cash flow yield
0
Debt to equity
0
Debt to assets
0
Net debt to EBITDA
0
Current ratio
0.21
Interest coverage
0
Income quality
0.02
Dividend Yield
0
Payout ratio
0
Sales general and administrative to revenue
0
Research and developement to revenue
0
Intangibles to total assets
0
Capex to operating cash flow
0
Capex to revenue
0
Capex to depreciation
0
Stock based compensation to revenue
0
Graham number
10.9
ROIC
0
Return on tangible assets
-0.06
Graham Net
-1.48
Working capital
-3.72M
Tangible asset value
1.47B
Net current asset value
-253.98M
Invested capital
0
Average receivables
0
Average payables
0
Average inventory
0
Days sales outstanding
0
Days payables outstanding
0
Days of inventory on hand
0
Receivables turnover
0
Payables turnover
0
Inventory turnover
0
ROE
-0.07
Capex per share
0

SRNG Frequently Asked Questions

What is Soaring Eagle Acquisition Corp. stock symbol ?

Soaring Eagle Acquisition Corp. is a US stock , located in New york of Ny and trading under the symbol SRNG

What is Soaring Eagle Acquisition Corp. stock quote today ?

Soaring Eagle Acquisition Corp. stock price is $1.74 today.

Is Soaring Eagle Acquisition Corp. stock public?

Yes, Soaring Eagle Acquisition Corp. is a publicly traded company.

Something similar

Top by Market Cap
Similar Market Cap